Robarts Research

Stroke Prevention Research
Dr. J. David Spence
&
Dr. Daniel Hackam

Home
Research Team Leaders
Dr. J. David Spence
Dr. Daniel G. Hackam
What We Do
How We Help Our Patients
Stroke Prevention:
What works
How You Can Help
Donations
Participate In A Study
Our Research
The Focus of Our Research
Current Research Projects
Plaque Measurement
The Beginning
2D Plaque Area
Measurement for
Genetic Research
3D Plaque Measurement For Atherosclerosis
New Treatment Evaluation
Dr. J. David Spence Publications
Internet Citations
Books
Publications for Download
Publications 2008 - 2010
Publications 2002-2007
Publications 1977-2001
Dr. Daniel G. Hackam Publications
Recent Publications
The SPARC Lab
Our Team
General Information
Strokes From Neck Injury
Links
How to Contact SPARC
Email SPARC

Valid XHTML 1.0 Transitional



Dr. Daniel G. Hackam Recent Publications

  1. J. David Spence and Daniel G. Hackam; Treating Arteries Instead of Risk Factors. A Paradigm Change in Management of Atherosclerosis; Stroke 2010, April 22; ISSN: 1524-4628.
  2. Hackam DG, Hackam AS. Translation of genetic discoveries into clinical therapies. Ann Intern Med. 2008 Feb 5;148(3):246-7.
  3. Garg AX, Hackam D, Tonelli M. Systematic review and meta-analysis: when one study is just not enough. Clin J Am Soc Nephrol. 2008 Jan;3(1):253-60.
  4. Hackam DG. The ankle brachial index independently predicted all-cause mortality in high-risk patients with peripheral arterial disease. Evid Based Med. 2007 Dec;12(6):187.
  5. Hackam DG, Leiter LA, Yan AT, Yan RT, Mendelsohn A, Tan M, Zavodni L, Chen R, Tsang JL, Kundi A, Lin PJ, Fitchett DH, Langer A, Goodman SG; Vascular Protection Registry and Guideline Oriented Appraoch to Lipid Lowering Registry Investigators. Missed opportunities for the secondary prevention of cardiovascular disease in Canada. Can J Cardiol. 2007 Dec;23(14):1124-30.
  6. Hackam DG. The ankle-brachial index independently predicted all-cause mortality in high-risk patients with peripheral arterial disease. ACP J Club. 2007 Nov-Dec;147(3):81.
  7. Hackam DG, Spence JD, Garg AX, Textor SC. Role of renin-angiotensin system blockade in atherosclerotic renal artery stenosis and renovascular hypertension. Hypertension. 2007 Dec;50(6):998-1003.
  8. Avner M, Finkelstein Y, Hackam D, Koren G. Establishing causality in pediatric adverse drug reactions : use of the naranjo probability scale. Paediatr Drugs. 2007;9:267-270.
  9. Hackam DG. Predicting stroke risk in patients with atrial fibrillation. Stroke. 2007;38:2409.
  10. Hackam DG. Review: antioxidant supplements for primary and secondary prevention do not decrease mortality. ACP J Club. 2007;147:4.
  11. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis. 2007;7:358-368.
  12. Hackam DG, Spence JD. Combining multiple approaches for the secondary prevention of vascular events after stroke: a quantitative modeling study. Stroke. 2007;38:1881-1885.
  13. Hackam DG. Translating animal research into clinical benefit. BMJ. 2007;334:163-164.
  14. Hackam DG. Intensive reduction of low-density lipoprotein-cholesterol: implications of recent trials. Am J Cardiovasc Drugs. 2006;6:367-371.
  15. Hackam DG, Eikelboom JW. Antithrombotic treatment for peripheral arterial disease. Heart. 2007;93:303-308.
  16. Hackam DG, Redelmeier DA. Translation of research evidence from animals to humans. JAMA. 2006;296:1731-1732.
  17. Hackam DG, Tan MK, Lin PJ et al. Supporting a call to action for peripheral artery disease: insights from two prospective clinical registries. J Vasc Surg. 2006;44:776-781.
  18. Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. Lancet. 2006;%19;368:659-665.
  19. Yan AT, Yan RT, Tan M et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med. 2006;119:676-683.
  20. Hackam DG. Medical management of peripheral arterial disease. JAMA. 2006;296:41-42.
  21. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins: panacea for sepsis? Lancet Infect Dis. 2006;6:242-248.
  22. Hackam DG. Perioperative beta-blocker therapy in vascular surgery: clinical update. J Vasc Surg. 2006;43:632-634.
  23. Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet. 2006;367:413-418.
  24. Hackam DG, Goodman SG, Anand SS. Management of risk in peripheral artery disease: recent therapeutic advances. Am Heart J. 2005;150:35-40.
  25. Hackam DG. Cardiovascular risk prevention in peripheral artery disease. J Vasc Surg. 2005;41:1070-1073.
  26. Hackam DG. Does intensified cholesterol lowering provide greater protection from cardiovascular events among patients with stable coronary artery disease? CMAJ. 2005;172:1294-1295.
  27. Hackam DG, Kopp A, Redelmeier DA. Prognostic implications of warfarin cessation after major trauma: a population-based cohort analysis. Circulation. 2005;111:2250-2256.
  28. Hackam DG, Tan MK, Honos GN, Leiter LA, Langer A, Goodman SG. How does the prognosis of diabetes compare with that of established vascular disease? Insights from the Canadian Vascular Protection (VP) Registry. Am Heart J. 2004;148:1028-1033.
  29. Hackam DG. The PROGRESS trial three years later: Clear and accurate interpretations of studies are needed. BMJ. 2004;329:1404.
  30. Hackam DG, Kapral MK. Progress in clinical neurosciences: pharmacotherapies for the secondary prevention of stroke. Can J Neurol Sci. 2004;31:295-303.
  31. Hackam DG, Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease. Semin Vasc Med. 2003;3:323-332.
  32. Hackam DG, Shumak SL. C-reactive protein for the prediction of cardiovascular risk: ready for prime-time? CMAJ. 2004;170:1563-1565.
  33. Hackam DG. Acarbose reduced the risk for cardiovascular disease and hypertension in impaired glucose tolerance. ACP J Club. 2004;140:2.
  34. Hackam DG. ACE inhibition in stable coronary artery disease. CMAJ. 2003;169:939.
  35. Hackam DG. Aldosterone blockade after myocardial infarction. CMAJ. 2003;169:444.
  36. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA. 2003;%20;290:932-940.
  37. Hackam D, Anand SS. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. Vasc Med. 2002;7:337-338.
  38. Hackam DG. Do hypertensive patients with average cholesterol levels benefit from atorvastatin therapy? CMAJ. 2003;168:1689.
  39. Hackam DG, Anand SS. Commentary: cardiovascular implications of the epidemiological transition for the developing world: Thailand as a case in point. Int J Epidemiol. 2003;32:468-469.
  40. Hackam DG. Treatment of chronic obstructive pulmonary disease: Combination or component therapy? CMAJ. 2003;168:1296-1297.
  41. Hackam DG. Long-term, low-intensity warfarin after idiopathic venous thromboembolism. CMAJ. 2003;168:1160-1161.
  42. Hackam DG. Drug treatment of hypertension. Conclusion of editorial is somewhat flawed. BMJ. 2003;326:764.
  43. Spence JD, Eliasziw M, DiCicco M, Hackam DG, Galil R, Lohmann T. Carotid plaque area: a tool for targeting and evaluating vascular preventive therapy. Stroke. 2002;33:2916-2922.
  44. Hackam DG, Thain LM, Abassakoor A, McKenzie FN, Spence JD. Trapped renal arteries: functional renal artery stenosis due to occlusion of the aorta in the arch and below the kidneys. Can J Cardiol. 2001;17:587-592.
  45. Hackam DG, Peterson JC, Spence JD. What level of plasma homocyst(e)ine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 micromol/L. Am J Hypertens. 2000;13:105-110.
  46. Hackam DG, Zwimpfer TJ. Congenital entrapment of the lateral cutaneous nerve of the calf presenting as a personal sensory neuropathy. Can J Neurol Sci. 1998;25:168-170.

Click For Top of Page
© 2008 Stroke Prevention & Atherosclerosis Research Centre (SPARC)

SPARC is Committed to Stroke Prevention